Eli Lilly and Boehringer Ingelheim will undercut Sanofi by 15% with Basaglar, a biosimilar version of the insulin blockbuster Lantus launched today in the US. Basaglar will also undercut Sanofi ...

that was similar to daily shots of Lantus and Tresiba. The safety and tolerability profile of efsitora was in line with those of the daily basal insulin therapies. These above results are also ...

Toujeo (insulin glargine [rDNA origin]) has ... found blood sugar control with Toujeo was comparable to Lantus, with an improved safety profile. The incidence of confirmed hypoglycaemia was ...